Vaccine: Expert says UK should be ‘cautious’ over success
When you subscribe we will use the information you provide to send you these newsletters.Sometimes they’ll include recommendations for other related newsletters or services we offer.Our Privacy Notice explains more about how we use your data, and your rights.You can unsubscribe at any time.
The UK’s vaccination programme has progressed with speed, with more than half of British adults now partly immunised. Figures show 57 percent – more than 30 million people – have now had one dose, with numbers of second doses growing in kind. There are currently two vaccines being rolled out as part of the programme and more approved jabs are now on the way.
When are the new Covid jabs expected to arrive?
Vaccine candidates in the UK receive a green light for rollout from the Medicines and Healthcare products Regulatory Agency (MHRA).
The organisation has so far approved the American-made Pfizer and Oxford-backed AstraZeneca vaccines.
Eligible adults have received one or two doses of either jab, but other candidates exist.
Moderna
Moderna is another American success, which became one of the first to report a high efficacy rate in its jab during late 2020.
A spokeswoman for the company said it would meet contractual obligations to the UK Government by April.
She said: “Moderna expect to begin deliveries to the UK in April, within the spring delivery window previously communicated.
“Moderna is on track to meet quarterly contractual commitments.”
Johnson and Johnson
Another American multinational company, Johnson and Johnson, has tasked its Belgian pharmaceutical arm, Janssen, with making a single-dose jab.
A spokesman confirmed they sought approval for the jab with the MHRA “as part of their ongoing rolling review seeking authorisation for our single-dose Janssen COVID-19 vaccine candidate.”
The Daily Telegraph confirmed the MHRA has started the process but has not released an expected approval date.
DON’T MISS
Chris Whitty issues warning as UK unlocks for first ‘Freedom Day’ – INSIGH
‘You are putting your family at risk!’ Covid rule breakers warned – VIDEO
Coronavirus is evolving daily mutations now: Expert warns of ‘army’ – ANALYSIS
Novavax
Novovax, which is manufacturing its vaccine candidate in Scotland, has turned out promising early efficacy results.
Researchers confirmed the jab protects against 89 percent of infections and 100 percent effective against severe disease.
The company said it would use these results to seek regulatory approval earlier this month, although there is no expected date just yet.
GSK with Sanofi Pasteur
Few other vaccines have emerged from their trials, but the closest to doing so is GSK’s candidate, which is currently nearing its penultimate stage.
The UK has ordered 60 million doses of the jab, which doesn’t have an efficacy rate yet.
A dosing error in its trials threw off its prospective approval dates from summer to the end of 2021.
Source: Read Full Article